Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133586) titled 'Low-Dose Immune Checkpoint Inhibitors Combined with Irinotecan for Third-Line Treatment of Advanced Gastric Cancer' on Sept. 29.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)
Condition:
gastric adenocarcinoma or gastroesophageal junction adenocarcinoma
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-10-01
Target Sample Size: experimental group:42;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?pr...